Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003428 · ClinicalTrials.gov registry record · Phase 2
Hormone Therapy in Treating Women With Breast Cancer
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 114
- Enrollment target
NCT00003428: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00003428 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 114 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003428, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 114 participants
- Enrollment target
Study Summary
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using arzoxifene hydrochloride may fight breast cancer by blocking the use of estrogen by the tumor cells. PURPOSE: This randomized phase II trial is comparing two different doses of arzoxifene hydrochloride to see how well it works in treating women with advanced or metastatic breast cancer.
Interventions
- DRUG arzoxifene hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 1998-05 |
| Est. Completion | 2001-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003428
The ClinicalTrials.gov registry entry for NCT00003428 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 114 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which arzoxifene hydrochloride is the first listed.
NCT00003428 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003428 about?
NCT00003428 is a clinical study titled "Hormone Therapy in Treating Women With Breast Cancer". RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using arzoxifene hydrochloride may fight breast cancer by blocking the use of estrogen by the tumor cells. PURPOSE: This randomized phase II trial is comparing two different doses of arzoxifene hydrochloride to see...
What is the current status of trial NCT00003428?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 114 participants. The study started on 1998-05. Estimated completion is 2001-06.
What interventions are being tested in trial NCT00003428?
The interventions under investigation include: arzoxifene hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00003428?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.